US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist
  • 0.580
  • -0.051-8.14%
Close Dec 13 16:00 ET
  • 0.586
  • +0.006+1.00%
Post 19:07 ET
148.44MMarket Cap-3.47P/E (TTM)

Adaptimmune Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
458.83%40.9M
2,399.63%128.23M
-88.07%5.68M
122.05%60.28M
-97.91%231K
4.45%7.32M
-7.37%5.13M
1,231.50%47.6M
341.50%27.15M
678.26%11.03M
Operating revenue
458.83%40.9M
2,399.63%128.23M
-88.07%5.68M
122.05%60.28M
-97.91%231K
4.45%7.32M
-7.37%5.13M
1,231.50%47.6M
341.50%27.15M
678.26%11.03M
Cost of revenue
Gross profit
Operating expense
3.02%55.58M
18.97%59.53M
24.18%54.94M
5.03%198.32M
39.23%50.09M
7.91%53.95M
1.52%50.04M
-17.39%44.24M
12.13%188.82M
-18.76%35.97M
Selling and administrative expenses
31.63%21.28M
-4.93%19.08M
5.55%19.73M
17.55%71.81M
30.63%16.88M
-3.87%16.16M
37.96%20.07M
11.25%18.69M
6.61%61.09M
-12.55%12.92M
-General and administrative expense
31.63%21.28M
-4.93%19.08M
5.55%19.73M
17.55%71.81M
30.63%16.88M
-3.87%16.16M
37.96%20.07M
11.25%18.69M
6.61%61.09M
-12.55%12.92M
Research and development costs
-9.22%34.3M
34.98%40.45M
37.81%35.21M
-0.95%126.51M
44.06%33.21M
13.88%37.79M
-13.74%29.97M
-30.49%25.55M
14.98%127.73M
-21.87%23.05M
Operating profit
68.52%-14.68M
252.98%68.7M
-1,566.54%-49.26M
14.62%-138.04M
-99.86%-49.86M
-8.47%-46.63M
-2.64%-44.91M
106.72%3.36M
0.36%-161.67M
41.80%-24.95M
Net non-operating interest income expense
-54.07%987K
-44.91%850K
98.96%1.35M
286.77%5.96M
205.16%1.6M
563.27%2.15M
332.21%1.54M
100.00%676K
40.82%1.54M
192.18%523K
Non-operating interest income
-2.47%2.1M
-10.82%1.38M
98.96%1.35M
286.77%5.96M
205.16%1.6M
563.27%2.15M
332.21%1.54M
100.00%676K
40.82%1.54M
192.18%523K
Non-operating interest expense
--1.11M
--526K
----
----
----
--0
--0
----
----
----
Other net income (expense)
-619.30%-3.09M
-97.81%497K
97.43%-61K
789.69%19.54M
91.84%-313K
-126.16%-430K
3,558.93%22.66M
-19,883.33%-2.37M
-173.55%-2.83M
-195.00%-3.83M
Special income (charges)
--0
--0
--0
985.76%20.35M
--0
---106K
--22.16M
---1.7M
---2.3M
---2.3M
-Less：Restructuring and merger&acquisition
--0
--0
--0
-985.76%-20.35M
--0
--106K
---22.16M
--1.7M
--2.3M
--2.3M
Other non- operating income (expenses)
-854.63%-3.09M
-0.80%497K
90.91%-61K
-50.56%-807K
79.64%-313K
-119.71%-324K
176.49%501K
-5,691.67%-671K
-113.91%-536K
-138.08%-1.54M
Income before tax
62.63%-16.79M
438.24%70.05M
-2,988.44%-47.98M
30.94%-112.54M
-71.90%-48.57M
-9.49%-44.91M
52.99%-20.71M
103.35%1.66M
-3.60%-162.96M
26.89%-28.26M
Income tax
20.96%831K
-22.65%526K
-15.84%526K
-46.50%1.34M
-166.00%-656K
72.18%687K
44.68%680K
-1.42%625K
215.68%2.5M
375.60%994K
Net income
61.37%-17.62M
425.03%69.52M
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
Net income continuous Operations
61.37%-17.62M
425.03%69.52M
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
Minority interest income
Net income attributable to the parent company
61.37%-17.62M
425.03%69.52M
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
61.37%-17.62M
425.03%69.52M
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
Basic earnings per share
66.67%-0.06
350.00%0.3
-2,970.81%-0.18
47.06%-0.54
0.00%-0.18
25.00%-0.18
60.00%-0.12
102.09%0.0063
0.00%-1.02
25.00%-0.18
Diluted earnings per share
66.67%-0.06
300.00%0.24
-2,996.68%-0.18
47.06%-0.54
0.00%-0.18
25.00%-0.18
60.00%-0.12
102.07%0.0062
0.00%-1.02
25.00%-0.18
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Total revenue 458.83%40.9M2,399.63%128.23M-88.07%5.68M122.05%60.28M-97.91%231K4.45%7.32M-7.37%5.13M1,231.50%47.6M341.50%27.15M678.26%11.03M
Operating revenue 458.83%40.9M2,399.63%128.23M-88.07%5.68M122.05%60.28M-97.91%231K4.45%7.32M-7.37%5.13M1,231.50%47.6M341.50%27.15M678.26%11.03M
Cost of revenue
Gross profit
Operating expense 3.02%55.58M18.97%59.53M24.18%54.94M5.03%198.32M39.23%50.09M7.91%53.95M1.52%50.04M-17.39%44.24M12.13%188.82M-18.76%35.97M
Selling and administrative expenses 31.63%21.28M-4.93%19.08M5.55%19.73M17.55%71.81M30.63%16.88M-3.87%16.16M37.96%20.07M11.25%18.69M6.61%61.09M-12.55%12.92M
-General and administrative expense 31.63%21.28M-4.93%19.08M5.55%19.73M17.55%71.81M30.63%16.88M-3.87%16.16M37.96%20.07M11.25%18.69M6.61%61.09M-12.55%12.92M
Research and development costs -9.22%34.3M34.98%40.45M37.81%35.21M-0.95%126.51M44.06%33.21M13.88%37.79M-13.74%29.97M-30.49%25.55M14.98%127.73M-21.87%23.05M
Operating profit 68.52%-14.68M252.98%68.7M-1,566.54%-49.26M14.62%-138.04M-99.86%-49.86M-8.47%-46.63M-2.64%-44.91M106.72%3.36M0.36%-161.67M41.80%-24.95M
Net non-operating interest income expense -54.07%987K-44.91%850K98.96%1.35M286.77%5.96M205.16%1.6M563.27%2.15M332.21%1.54M100.00%676K40.82%1.54M192.18%523K
Non-operating interest income -2.47%2.1M-10.82%1.38M98.96%1.35M286.77%5.96M205.16%1.6M563.27%2.15M332.21%1.54M100.00%676K40.82%1.54M192.18%523K
Non-operating interest expense --1.11M--526K--------------0--0------------
Other net income (expense) -619.30%-3.09M-97.81%497K97.43%-61K789.69%19.54M91.84%-313K-126.16%-430K3,558.93%22.66M-19,883.33%-2.37M-173.55%-2.83M-195.00%-3.83M
Special income (charges) --0--0--0985.76%20.35M--0---106K--22.16M---1.7M---2.3M---2.3M
-Less：Restructuring and merger&acquisition --0--0--0-985.76%-20.35M--0--106K---22.16M--1.7M--2.3M--2.3M
Other non- operating income (expenses) -854.63%-3.09M-0.80%497K90.91%-61K-50.56%-807K79.64%-313K-119.71%-324K176.49%501K-5,691.67%-671K-113.91%-536K-138.08%-1.54M
Income before tax 62.63%-16.79M438.24%70.05M-2,988.44%-47.98M30.94%-112.54M-71.90%-48.57M-9.49%-44.91M52.99%-20.71M103.35%1.66M-3.60%-162.96M26.89%-28.26M
Income tax 20.96%831K-22.65%526K-15.84%526K-46.50%1.34M-166.00%-656K72.18%687K44.68%680K-1.42%625K215.68%2.5M375.60%994K
Net income 61.37%-17.62M425.03%69.52M-4,781.76%-48.5M31.18%-113.87M-63.82%-47.92M-10.09%-45.6M51.96%-21.39M102.06%1.04M-4.66%-165.46M24.73%-29.25M
Net income continuous Operations 61.37%-17.62M425.03%69.52M-4,781.76%-48.5M31.18%-113.87M-63.82%-47.92M-10.09%-45.6M51.96%-21.39M102.06%1.04M-4.66%-165.46M24.73%-29.25M
Minority interest income
Net income attributable to the parent company 61.37%-17.62M425.03%69.52M-4,781.76%-48.5M31.18%-113.87M-63.82%-47.92M-10.09%-45.6M51.96%-21.39M102.06%1.04M-4.66%-165.46M24.73%-29.25M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 61.37%-17.62M425.03%69.52M-4,781.76%-48.5M31.18%-113.87M-63.82%-47.92M-10.09%-45.6M51.96%-21.39M102.06%1.04M-4.66%-165.46M24.73%-29.25M
Basic earnings per share 66.67%-0.06350.00%0.3-2,970.81%-0.1847.06%-0.540.00%-0.1825.00%-0.1860.00%-0.12102.09%0.00630.00%-1.0225.00%-0.18
Diluted earnings per share 66.67%-0.06300.00%0.24-2,996.68%-0.1847.06%-0.540.00%-0.1825.00%-0.1860.00%-0.12102.07%0.00620.00%-1.0225.00%-0.18
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion--------Unqualified Opinion--
Heat List
US
Overall
Symbol
Price
% Chg

No Data

Investment Theme CAR-T Therapy
CAR-T Therapy
Intraday-0.08%